TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Authors
Keywords
-
Journal
Cancer Discovery
Volume 12, Issue 11, Pages 2516-2529
Publisher
American Association for Cancer Research (AACR)
Online
2022-10-11
DOI
10.1158/2159-8290.cd-22-0332
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME
- (2022) Tim Grob et al. BLOOD
- A Randomized Phase 2 Trial of Azacitidine ± Durvalumab as First-line Therapy for Higher-Risk Myelodysplastic Syndromes
- (2022) Amer M. Zeidan et al. Blood Advances
- TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
- (2022) Olga K Weinberg et al. Blood Advances
- TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia
- (2022) Mehrnoosh Tashakori et al. BLOOD
- Additional cytogenetic features determines outcome in patients allografted for TP53 mutant acute myeloid leukemia
- (2022) Justin Loke et al. CANCER
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data
- (2022) Daniel A. Arber et al. BLOOD
- First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
- (2022) Ecaterina Elena Dumbrava et al. JOURNAL OF CLINICAL ONCOLOGY
- APR-246 induces early cell death by ferroptosis in acute myeloid leukemia.
- (2021) Rudy Birsen et al. HAEMATOLOGICA
- Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
- (2021) David A. Sallman et al. JOURNAL OF CLINICAL ONCOLOGY
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
- (2021) Thomas Cluzeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
- (2021) Anthony M. Hunter et al. Blood Advances
- Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
- (2021) Rachel Thijssen et al. BLOOD
- T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
- (2021) Naval Daver et al. LEUKEMIA
- Outcomes of TP53 ‐mutant acute myeloid leukemia with decitabine and venetoclax
- (2021) Kunhwa Kim et al. CANCER
- Outcomes in patients with newly diagnosed TP53 ‐mutated acute myeloid leukemia with or without venetoclax‐based therapy
- (2021) Sangeetha Venugopal et al. CANCER
- Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway
- (2021) Abhishek Maiti et al. Clinical Lymphoma Myeloma & Leukemia
- The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis.
- (2021) Hui Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
- (2021) Ryunosuke Saiki et al. NATURE MEDICINE
- Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
- (2021) David A. Sallman et al. BLOOD
- Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
- (2021) Guillermo Garcia-Manero et al. BLOOD
- Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
- (2021) Andrew M. Brunner et al. BLOOD
- Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents
- (2021) Daniel A. Pollyea et al. BLOOD
- Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
- (2021) Naval Daver et al. BLOOD
- p53 partial loss-of-function mutations sensitize to chemotherapy
- (2021) Boris Klimovich et al. ONCOGENE
- Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia
- (2021) Amer M. Zeidan et al. Blood Advances
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
- (2020) David A Sallman et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
- (2020) Arnold J. Levine INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- p53, cancer and the immune response
- (2020) Julianna Blagih et al. JOURNAL OF CELL SCIENCE
- A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
- (2020) Rebecca Epperly et al. Frontiers in Oncology
- Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
- (2020) Jan Philipp Bewersdorf et al. LEUKEMIA & LYMPHOMA
- TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
- (2020) David A. Sallman et al. BLOOD
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- (2020) Elsa Bernard et al. NATURE MEDICINE
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting p53 for the treatment of cancer
- (2020) Michael J. Duffy et al. SEMINARS IN CANCER BIOLOGY
- Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
- (2020) Geoffrey L Uy et al. BLOOD
- Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations — A Distinct Stem Cell Disorder
- (2020) Heinz Sill et al. CLINICAL CANCER RESEARCH
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis
- (2020) Kelly L. Bolton et al. NATURE GENETICS
- TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
- (2020) Jayakumar Vadakekolathu et al. Blood Advances
- A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition
- (2020) Anita G. Koshy et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
- (2020) Shuo Chen et al. CANCER CELL
- Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
- (2020) Charles Craddock et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
- (2020) Nicholas J. Short et al. Blood Advances
- Signaling Regulatory Protein (SIRP)α-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition
- (2019) André Veillette et al. JOURNAL OF CLINICAL ONCOLOGY
- Current status and new treatment approaches in TP53 mutated AML
- (2019) Anthony M. Hunter et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- ERCC6L2 defines a novel entity within inherited acute myeloid leukemia
- (2019) Suvi P. M. Douglas et al. BLOOD
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
- (2019) Lawrence A. Donehower et al. Cell Reports
- The role of TP53 in acute myeloid leukemia: Challenges and opportunities
- (2019) Karina Barbosa et al. GENES CHROMOSOMES & CANCER
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
- (2019) Steffen Boettcher et al. SCIENCE
- Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation
- (2019) Lia Minculescu et al. Frontiers in Immunology
- Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
- (2019) Farhad Ravandi et al. Lancet Haematology
- Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress
- (2019) Irem Kaymak et al. CANCER RESEARCH
- Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer
- (2019) Yanni Zhu et al. Cell Stem Cell
- Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
- (2019) Lionel Low et al. Nature Communications
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
- (2019) Christopher S. Hourigan et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
- (2019) Sisi Chen et al. Nature Communications
- Targeting TP53 Mutations in Myelodysplastic Syndromes
- (2019) Anthony M. Hunter et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- T-cell responses toTP53"hotspot" mutations and unique neoantigens expressed by human ovarian cancers
- (2018) Drew C Deniger et al. CLINICAL CANCER RESEARCH
- Investigational CD33-targeted therapeutics for acute myeloid leukemia
- (2018) Roland B. Walter EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
- (2018) Prajwal Boddu et al. LEUKEMIA & LYMPHOMA
- Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer
- (2018) Shannon N. Westin et al. CANCER RESEARCH
- Mutational processes shape the landscape of TP53 mutations in human cancer
- (2018) Andrew O. Giacomelli et al. NATURE GENETICS
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
- (2018) Patrick Williams et al. CANCER
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
- (2018) Naval Daver et al. Cancer Discovery
- Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
- (2018) Nicholas J Short et al. Lancet Haematology
- Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
- (2017) Laurence Lodé et al. HAEMATOLOGICA
- Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
- (2017) Frank G. Rücker et al. HAEMATOLOGICA
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- Decitabine in TP53-Mutated AML
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
- (2017) R. Coleman Lindsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
- (2017) Laurence Lodé et al. HAEMATOLOGICA
- Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
- (2017) Frank G. Rücker et al. HAEMATOLOGICA
- TP53mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
- (2016) Tapan M. Kadia et al. CANCER
- Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
- (2016) Matteo G. Della Porta et al. JOURNAL OF CLINICAL ONCOLOGY
- Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
- (2016) Yu Liu et al. NATURE
- Targeting mutant p53 through the mevalonate pathway
- (2016) William Freed-Pastor et al. NATURE CELL BIOLOGY
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
- (2016) Monika Belickova et al. Oncotarget
- PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
- (2016) Phaik Ju Teoh et al. Oncotarget
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
- (2015) Yoshikane Kikushige et al. Cell Stem Cell
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
- (2015) D A Sallman et al. LEUKEMIA
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- Chromothripsis from DNA damage in micronuclei
- (2015) Cheng-Zhong Zhang et al. NATURE
- A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
- (2015) Gurunadh R. Chichili et al. Science Translational Medicine
- Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice
- (2014) A. Stoddart et al. BLOOD
- PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
- (2014) B. Tessoulin et al. BLOOD
- Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
- (2014) Rebekka K. Schneider et al. CANCER CELL
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
- (2014) Terrence N. Wong et al. NATURE
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
- (2013) X Peng et al. Cell Death & Disease
- Mutant p53: one name, many proteins
- (2012) W. A. Freed-Pastor et al. GENES & DEVELOPMENT
- High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
- (2011) F. Vergez et al. HAEMATOLOGICA
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
- (2010) Yoshikane Kikushige et al. Cell Stem Cell
- The Tumor Suppressor p53: From Structures to Drug Discovery
- (2010) A. C. Joerger et al. Cold Spring Harbor Perspectives in Biology
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More